Moderna

MRNA48

S&P500

$72.89arrow_drop_down0.74%-$0.55

S&P500

MRNA48

$72.89

arrow_drop_down0.74%-$0.55

S&P500

Performance History

Key Stats
Open	$73.44
Prev. Close	$73.44
EPS	-15.35
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	71.65	73.60
52 Week Range	62.55	170.47

Ratios







EPS	-15.35

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Moderna (MRNA)

Moderna Inc (MRNA) is a biotechnology company that focuses on the development and commercialization of mRNA-based therapeutics and vaccines. The company's main product candidate is mRNA-1273, a vaccine against COVID-19. Moderna is also involved in developing mRNA-based therapies for various other diseases, including cancer and rare genetic disorders. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna's stock price has experienced significant volatility over the years. In its early years, the stock price remained relatively flat. However, in 2020, as the COVID-19 pandemic hit the world, Moderna's stock price surged on the back of positive news regarding its vaccine candidate. The stock reached its all-time high in late 2020 but has since experienced some pullbacks.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Stephane Bancel
Headquarters: Cambridge
Employees: 3900
Exchange: NASDAQ

Keep an eye on Moderna

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Moderna 's (MRNA) price per share?

The current price per share for Moderna (MRNA) is $72.89. The stock has seen a price change of -$0.55 recently, indicating a -0.75% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Moderna (MRNA)?

For Moderna (MRNA), the 52-week high is $170.47, which is 133.87% from the current price. The 52-week low is $62.55, the current price is 16.53% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Moderna (MRNA) a growth stock?

Moderna (MRNA) has shown an average price growth of 0.41% over the past three years. It has received a score of 32 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Moderna as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Moderna (MRNA) stock price performance year to date (YTD)?

As of the latest data, Moderna (MRNA) has a year-to-date price change of -35.21%. Over the past month, the stock has experienced a price change of -11.43%. Over the last three months, the change has been -52.88%. Over the past six months, the figure is -25.7%. Looking at a longer horizon, the five-year price change stands at 359.01%.

help

Is Moderna (MRNA) a profitable company?

Moderna (MRNA) has a net income of -$4.71B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 30.52% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -565.56% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $6.75B, although specific revenue growth data is currently not available. The gross profit is $2.06B. Operating income is noted at -$4.24B. Furthermore, the EBITDA is -$4.11B.

help

What is the market capitalization of Moderna (MRNA)?

Moderna (MRNA) has a market capitalization of $28.02B. The average daily trading volume is 3.55M, indicating the stock's liquidity and investor engagement.

News

Is It Time to Buy August's Worst-Performing Nasdaq Stocks?

Is It Time to Buy August's Worst-Performing Nasdaq Stocks?

Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows

Could This Be the Catalyst Novavax Needs to Get Its Stock Rallying Again?

Moderna, Inc. Shareholders - Robbins LLP Reminds MRNA Stockholders of the Class Action Lawsuit Against the Company – Seek Counsel Today

MRNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!